The short answer
Melatonin may add to chlorpromazine-related sleepiness. The exact clinical risk is not quantified, and laboratory or animal studies do not establish a safe dose or timing plan.
What this answer covers
Oral chlorpromazine with the exact supplement preparation described.
- Supplement or preparation
- Melatonin
- Medication ingredient
- chlorpromazine
Both products can affect alertness
Chlorpromazine can cause drowsiness. Melatonin can also make people sleepy, with longer-lasting daytime effects possible in some older adults. This supports discussing the actual product and dose.
Sleepiness and measured performance are different
A small placebo-controlled study of afternoon melatonin found greater subjective sleepiness after a prolonged task, but no overall adverse effect on its objective driving-test battery. This does not mean every dose causes measurable impairment.
The exact laboratory finding is not a patient estimate
Chlorpromazine reduced melatonin turnover in rat liver microsomes. The experiment did not measure human oral co-use, next-day alertness or the effect of spacing the products. It should not be described as a proven clinical rise in melatonin exposure.
Review the actual products
Bring the supplement label and your full medication list to the pharmacist, especially if chlorpromazine already affects alertness. Avoid driving when sleepy or impaired. No supplement dose or short spacing interval has been established to prevent overlapping effects.
Evidence and practical considerations
Side effects & toxicity
Melatonin may add to chlorpromazine-related sleepiness. The exact clinical risk is not quantified, and laboratory or animal studies do not establish a safe dose or timing plan.
- Exact scope
- Oral chlorpromazine with the exact supplement preparation described. with Oral chlorpromazine with the stated label and formulation limits.
- Medication form and route
- oral
What remains uncertain
- Conditional alertness review, with the standalone objective-performance null finding retained. Animal and laboratory results do not establish human pharmacokinetics or an adverse-event rate. Experimental light-phase differences do not provide a patient dosing rule.
Factors that may matter: Exact preparation and amount; Other medicines; Seizure history, alertness or electrolyte status where relevant.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral chlorpromazine.
May cause initial drowsiness, intensify other CNS depressants, lower the seizure threshold and cause photosensitivity. Has strong antiadrenergic and weaker peripheral anticholinergic effects.
How this applies: Exact ingredient and oral-route clinical context.
Label class warnings do not establish every exact botanical interaction, event rate or protective supplement interval.
Source 2: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Sleepiness is a possible effect. Older people may have prolonged daytime drowsiness; commercial products and long-term safety data vary.
How this applies: Supports conditional alertness review without claiming every dose objectively impairs performance.
General guidance does not quantify this exact medication combination or establish a universal protective interval.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty healthy adults in a crossover.
Subjective sleepiness increased after a prolonged task, but the overall objective driving-test battery did not show impairment.
How this applies: Supports nuance between sleepiness and measured performance.
Small single-dose study without the target antipsychotic. Subjective sleepiness and objective performance are different outcomes.
Source 4: Original laboratory study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Rat liver microsomal experiments.
Chlorpromazine reduced melatonin turnover under laboratory conditions.
How this applies: Exact materials mechanism study with major species and exposure limits.
Not a human oral melatonin combination or an estimate of clinical sedation; endogenous melatonin observations answer a different question.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked draft with exact preparation limits, original study findings and uncertainty. Clinical review not recorded. | |
| Research summary published |
Article revision: 69d4b26bb730f486
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.